三种抗惊厥药物治疗癫痫持续状态的随机试验
该随机、盲法、适应性试验纳入384例对苯二氮䓬类治疗无反应的儿童和成人惊厥性癫痫持续状态患者,随机接受左乙拉西坦(145例)、磷苯妥英(118例)或丙戊酸(121例)静脉治疗。主要终点为开始输注药物后60分钟临床惊厥消失且意识水平改善、未追加抗惊厥药,三组分别达到47%(95%可信区间39-55)、45%(36-54)和46%(38-55)。因预设的无效性停止规则,试验在中期分析后提前终止。三药不良事件发生率相似,差异无统计学意义。
要点
- 苯二氮䓬类难治性惊厥性癫痫持续状态患者中,左乙拉西坦、磷苯妥英、丙戊酸静脉给药后60分钟止惊并改善意识的比例分别约为47%、45%、46%,三药相似。
- 该试验因预设的无效性停止规则在中期分析后提前终止,未发现某一药物优于或劣于其他药物。
- 磷苯妥英组低血压和插管例数数值上较多,左乙拉西坦组死亡例数数值上较多,但差异均无统计学意义。
- 纳入患者中10%经判定为心因性发作。
- 三药不良事件发生率相似。
适用人群与场景
- 对苯二氮䓬类治疗无反应的儿童和成人惊厥性癫痫持续状态患者。
处置流程与药物剂量
- 对苯二氮䓬类无反应的惊厥性癫痫持续状态患者,可静脉给予左乙拉西坦、磷苯妥英或丙戊酸;原文未给出具体剂量、给药频次或疗程。
研究设计与关键结果
- 随机、盲法、适应性试验,纳入384例对苯二氮䓬类无反应的儿童和成人惊厥性癫痫持续状态患者,随机接受左乙拉西坦(145例)、磷苯妥英(118例)或丙戊酸(121例);因预设无效性停止规则在中期分析后提前终止。
- 主要终点(开始输注后60分钟临床惊厥消失且意识水平改善、未追加抗惊厥药)达到率:左乙拉西坦47%(95%可信区间39-55),磷苯妥英45%(36-54),丙戊酸46%(38-55)。
- 各药为最有效药物的后验概率分别为左乙拉西坦0.41、磷苯妥英0.24、丙戊酸0.35。
- 磷苯妥英组低血压和插管例数数值上较多,左乙拉西坦组死亡例数数值上较多,但差异无统计学意义。
- 纳入患者中10%经判定为心因性发作。
证据类型、等级与局限
- 证据类型:随机、盲法、适应性试验(ESETT,ClinicalTrials.gov NCT01960075),由美国国家神经疾病与卒中研究所资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对苯二氮䓬类难治性惊厥性癫痫持续状态,左乙拉西坦、磷苯妥英、丙戊酸三药在60分钟止惊并改善意识方面效果相似,选择时可综合考虑;原文未据此给出具体推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The choice of drugs for patients with status epilepticus that is refractory to treatment with benzodiazepines has not been thoroughly studied.
METHODS: In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines. The primary outcome was absence of clinically evident seizures and improvement in the level of consciousness by 60 minutes after the start of drug infusion, without additional anticonvulsant medication. The posterior probabilities that each drug was the most or least effective were calculated. Safety outcomes included life-threatening hypotension or cardiac arrhythmia, endotracheal intubation, seizure recurrence, and death.
RESULTS: A total of 384 patients were enrolled and randomly assigned to receive levetiracetam (145 patients), fosphenytoin (118), or valproate (121). Reenrollment of patients with a second episode of status epilepticus accounted for 16 additional instances of randomization. In accordance with a prespecified stopping rule for futility of finding one drug to be superior or inferior, a planned interim analysis led to the trial being stopped. Of the enrolled patients, 10% were determined to have had psychogenic seizures. The primary outcome of cessation of status epilepticus and improvement in the level of consciousness at 60 minutes occurred in 68 patients assigned to levetiracetam (47%; 95% credible interval, 39 to 55), 53 patients assigned to fosphenytoin (45%; 95% credible interval, 36 to 54), and 56 patients assigned to valproate (46%; 95% credible interval, 38 to 55). The posterior probability that each drug was the most effective was 0.41, 0.24, and 0.35, respectively. Numerically more episodes of hypotension and intubation occurred in the fosphenytoin group and more deaths occurred in the levetiracetam group than in the other groups, but these differences were not significant.
CONCLUSIONS: In the context of benzodiazepine-refractory convulsive status epilepticus, the anticonvulsant drugs levetiracetam, fosphenytoin, and valproate each led to seizure cessation and improved alertness by 60 minutes in approximately half the patients, and the three drugs were associated with similar incidences of adverse events. (Funded by the National Institute of Neurological Disorders and Stroke; ESETT ClinicalTrials.gov number, NCT01960075.).
参考来源
- Kapur J, Elm J, Chamberlain JM, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019. PMID: 31774955. doi:10.1056/NEJMoa1905795
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。